JOHNSON & JOHNSON — Director's Dealing 2025

Sep 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2025-09-04

Reporting Person: Taubert Jennifer L (EVP, WWC. Innovative Medicine)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-04	Common Stock	M	56471	$101.87	Acquired	234484.001	Direct
2025-09-04	Common Stock	S	56471	$177.806	Disposed	178013.001	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-09-04	Employee Stock Options (Right to Buy)	$101.87	M	56471	Disposed	2026-02-08	Common Stock (56471)	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $177.715 to $177.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Vested and exercisable one day after the third anniversary of the date of the grant.